Health Tech: Using data and crowdsourcing to fight cancer

Health Tech: Using data and crowdsourcing to fight cancer

Sep 14, 2017 · 27 min

People

  • Claire McGreane Host
  • Dr. Tony Blau Guest

Listen on

Suggest an edit

Dr. Tony Blau saw a big problem with cancer treatment: we can’t make sense of all the data we can gather. So he founded a startup that connects experts, doctors and patients to sort through their data and build an ever-smarter cancer database. We speak with Blau on this episode of GeekWire’s Health Tech podcast. For more Health Tech stories visit GeekWire.com/healthtech. Thank you to our sponsor, Providence St. Joseph Health’s Digital and Innovation Group. Follow them at twitter.com/provinnovation See omnystudio.com/listener for privacy information.

Seattle Tacoma International Airport Mark Long Tony Blau Tony Blau Houston

Chapters

  1. 0:00 Introduction to the power of the internet and its application to healthcare
  2. 2:10 Sponsor message: Providence St. Joseph Health's Digital and Innovation Group
  3. 2:44 Announcement: Health Tech Live Show with Mark Long
  4. 3:50 Tony Blau's background and motivation for his work
  5. 5:11 Next-generation sequencing and personalized medicine
  6. 6:58 The Center for Cancer Innovation and learning from patient experiences
  7. 7:57 Focus on triple-negative breast cancer and crowdsourcing expertise
  8. 10:46 Tony Blau's personal experience with myeloma and its impact on his work
  9. 13:10 Introduction to All for Cure
  10. 13:24 Sponsor message: Providence St. Joseph Health's Digital and Innovation Group (continued)
  11. 14:17 All for Cure: A platform for patients and experts
  12. 16:04 How All for Cure works: Personalized dashboards and community input
  13. 17:54 Data storage and the broader goals of All for Cure
  14. 18:27 Discussion panel and expert contributions
  15. 19:34 All for Cure's unique approach compared to other personalized medicine initiatives
  16. 19:57 Challenges with medical records and the value of granular data

Conversation

No comments yet.